Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rituximab for autoimmune blistering diseases: recent studies, new insights.

Literature DB >> 22648328

Rituximab for autoimmune blistering diseases: recent studies, new insights.

Abstract

Rituximab, an anti-CD20 monoclonal antibody, has been successfully used off-label for treatment of autoimmune blistering diseases. We discuss rituximab mechanisms of action, host factors that may affect response to rituximab, and the efficacy and safety of rituximab in autoimmune blistering diseases, incorporating recent data on the use of rituximab in other autoimmune disease patients.

Entities: Chemical Disease Gene Mutation Species

Mesh：

Substances：

Year: 2012 PMID： 22648328 PMCID： PMC3621036

Source DB: PubMed Journal: G Ital Dermatol Venereol ISSN： 0392-0488 Impact factor: 2.011

69 in total

1. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.

Authors: Dedee F Murrell; Sarah Dick; A R Ahmed; Masayuki Amagai; Maria A Barnadas; Luca Borradori; Jean-Claude Bystryn; Giuseppe Cianchini; Luis Diaz; David Fivenson; Russell Hall; Karen E Harman; Takashi Hashimoto; Michael Hertl; Nico Hunzelmann; Pilar Iranzo; Pascal Joly; Marcel F Jonkman; Yasuo Kitajima; Neil J Korman; Linda K Martin; Daniel Mimouni; Amit G Pandya; Aimee S Payne; David Rubenstein; Hiroshi Shimizu; Animesh A Sinha; David Sirois; Detlef Zillikens; Victoria P Werth
Journal: J Am Acad Dermatol Date: 2008-03-14 Impact factor: 11.527

2. A new approach on bullous pemphigoid therapy.

Authors: Z Saouli; A Papadopoulos; G Kaiafa; F Girtovitis; Z Kontoninas
Journal: Ann Oncol Date: 2008-03-05 Impact factor: 32.976

3. Severe bullous pemphigoid in an infant--successful treatment with rituximab.

Authors: Johannes Schulze; Peter Bader; Ulrike Henke; Markus A Rose; Stefan Zielen
Journal: Pediatr Dermatol Date: 2008 Jul-Aug Impact factor: 1.588

4. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy.

Authors: R Saraceno; L Citarella; G Spallone; S Chimenti
Journal: Clin Exp Dermatol Date: 2007-11-16 Impact factor: 3.470

5. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy.

Authors: E Keystone; G R Burmester; R Furie; J E Loveless; P Emery; J Kremer; P P Tak; M S Broder; E Yu; M Cravets; F Magrini; F Jost
Journal: Arthritis Rheum Date: 2008-06-15

6. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.

Authors: A Kavanaugh; S Rosengren; S J Lee; D Hammaker; G S Firestein; K Kalunian; N Wei; D L Boyle
Journal: Ann Rheum Dis Date: 2007-07-20 Impact factor: 19.103

7. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.

Authors: Stefan Beissert; Thomas Werfel; Uta Frieling; Markus Böhm; Michael Sticherling; Rudolf Stadler; Detlef Zillikens; Berthold Rzany; Nicolas Hunzelmann; Michael Meurer; Harald Gollnick; Thomas Ruzicka; Hans Pillekamp; Volker Junghans; Gisela Bonsmann; Thomas A Luger
Journal: Arch Dermatol Date: 2007-12

8. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.

Authors: Y K Onno Teng; E W Nivine Levarht; Mojtaba Hashemi; Ingeborg M Bajema; René E M Toes; Tom W J Huizinga; Jacob M van Laar
Journal: Arthritis Rheum Date: 2007-12

9. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.

Authors: Philip J Mease; Dennis A Revicki; Jacek Szechinski; Maria Greenwald; Alan Kivitz; Leonor Barile-Fabris; Jatinderpal Kalsi; Jennifer Eames; Marjatta Leirisalo-Repo
Journal: J Rheumatol Date: 2007-11-15 Impact factor: 4.666

Rituximab for autoimmune blistering diseases: recent studies, new insights.

1. Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus.

2. A new approach on bullous pemphigoid therapy.

3. Severe bullous pemphigoid in an infant--successful treatment with rituximab.

4. A biological approach in a patient with psoriasis and bullous pemphigoid associated with losartan therapy.

5. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy.

6. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results.

7. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid.

8. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.

9. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.

10. Bullous pemphigoid and pemphigus vulgaris--incidence and mortality in the UK: population based cohort study.

Review 1. [Pemphigus. Model disease for targeted therapy].

Review 2. Diabetes tolerogenic vaccines targeting antigen-specific inflammation.

Review 3. Immunosuppressive peptides and their therapeutic applications.

Review 4. The role of intravenous immunoglobulin in treatment of mucous membrane pemphigoid: A review of literature.